EPIGENETIC DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS
In order to respond effectively to the current Covid-19 outbreak, the European Institute of Oncology has established a new line of research aimed at identifying new potential therapeutics for SARS-CoV-2-infected patients.
The Epi-Drugs research program has been recently established by IEO to contribute containing the spread of the current Covid-19 pandemics. Based on the drug repurposing approach, the program aims at reaching the Covid-19 patients as quickest as possible, through the repurposing of already-available epigenetic drugs, either approved or in late-stage development (i.e. IEO proprietary compounds and their combinations). Epigenetic drugs that are effective against the virus replicative cycle have been identified, and are currently under validation in murine coronavirus infection models to prove their efficacy, especially in the early phases of the infection. In addition, the program involves the development of a screening method for new epigenetic drugs and targets that will help to design more effective therapies in the expectation of any future viral pandemics.
- Treatment of Covid-19 disease;
- Treatment of viral infections.
- Reduced time and costs associated with the antiviral drug development;
- Proprietary epigenetic compounds under preclinical evaluation for other indication;
- Established network with national and international players on the front lines of the fight against Covid-19.